PERTH, AUSTRALIA: December 12, 2011 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a public Australian peptide drug discovery company, announced today the successful completion of the first stage of its collaboration with Pfizer to discover novel peptide-based vaccines. Under the terms of the agreement, Phylogica will receive an undisclosed milestone payment.
For further information please download PDF below:
